1stOncology™: Cancer Intelligence Service – Page 8234 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Selecta Biosciences to Participate in Jefferies Virtual Gene Therapy/Editing Summit

On October 20, 2021 Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, reported that Company’s Management will provide a corporate update and participate in one-on-one investor meetings at the Jefferies Virtual Gene Therapy/Editing Summit to be held October 27-28, 2021 (Press release, Selecta Biosciences, OCT 20, 2021, View Source [SID1234591595]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Details on the conference can be found below.

Jefferies Virtual Gene Therapy/Editing Summit
Format: Presentation and one-on-one investor meetings
Date: Wednesday October 27, 2021
Presentation Time: 11:00 a.m. EST
Webcast: Click Here

An archived webcast will also be accessible in the Investors & Media section of the company’s website at www.selectabio.com.

QIAGEN N.V. to Release Results for Q3 2021 and First Nine Months of 2021

On October 20, 2021 QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) reported that it plans to release its report on results for the third quarter and first nine months of 2021 on Wednesday, November 3, at approximately 21:05 Central European Time (CET) / 16:05 Eastern Daylight Time (EDT) (Press release, Qiagen, OCT 20, 2021, View Source [SID1234591594]).

A conference call is scheduled for Thursday, November 4 at 14:30 Frankfurt time /13:30 London time/ 9:30 New York time. It will be hosted by Thierry Bernard, Chief Executive Officer, and Roland Sackers, Chief Financial Officer. (For Europe: Due to the U.S. time switch, the timing of our investor conference call will be held 30 minutes earlier than usual.)

Orum Therapeutics to Participate in SVB Leerink Biopharma Private Company Connect

On October 20, 2021 Orum Therapeutics, a preclinical biotech pioneering the development of tumor-directed targeted protein degraders to improve cancer treatment, reported that members of its management team will be participating in the SVB Leerink Biopharma Private Company Connect Event (Press release, Orum Therapeutics, OCT 20, 2021, View Source [SID1234591592]). The event will take place virtually October 27-29, 2021.

OncoMyx Announces Presentations at IOVC 2021 on the Use of Multi-Armed Myxoma Virus as a Novel Oncolytic Immunotherapy

On October 20, 2021 OncoMyx Therapeutics, a privately-held oncolytic immunotherapy company, reported four presentations at the upcoming 2021 International Oncolytic Virus Conference (IOVC) being held November 5-7, 2021, both virtually and in Sedona, Ariz (Press release, OncoMyx Therapeutics, OCT 20, 2021, View Source [SID1234591591]). The company plans to present recent preclinical data demonstrating oncolytic activity, transgene production, immunomodulatory mechanisms of action, and efficacy of intratumoral (IT) and intravenous (IV) administration of OncoMyx’s multi-armed myxoma virotherapy for the treatment of cancer.

OncoMyx Talk and Poster Info

Session 1: Novel Payloads and Mechanisms of Action 1 with Leslie Sharp, PhD, CSO, will happen Friday, Nov. 5th from 8:55am – 9:20am MST
Poster Presentation (Virtual) with Lina Franco, PhD, Scientist II, is available on demand Friday, Nov. 5th – Sunday, Nov. 7th
A Special Session with Steve Potts, PhD, MBA, CEO and cofounder, entitled "Benefits of a systemic-delivered, multi-armed non-human pathogen, myxoma virus, against solid and heme cancers" will take place Saturday, Nov. 6th from 8:44pm – 8:56pm MST.
A Live Q&A for the poster presentation with Dr. Franco will be held Sunday, Nov. 7th from 1:00pm – 3:30pm MST.
The poster will be available on OncoMyx’s website on November 5th.

About Oncolytic Immunotherapy and Myxoma Virus

Oncolytic viruses (OV) selectively replicate in and lyse tumor cells and provide stimulation to the immune system, representing a promising therapeutic option in development to treat cancers that do not respond well to treatment with immune checkpoint inhibitors. Myxoma virus (MYXV) is a member of the Pox family of double stranded DNA viruses. The natural host of MYXV is a subset of rabbits and hares, but MYXV is able to infect cancer cell lines of humans and other species. The genome of MYXV is relatively large and is amenable to engineering for expression of transgenic proteins, making it an excellent oncolytic virus for introduction of immunomodulatory proteins.

OncoMyx Announces Presentations at SITC 2021 of New Data Demonstrating the Potential of a Multi-Armed Myxoma Virus as a Novel Oncolytic Immunotherapy for Multiple Myeloma

On October 20, 2021 OncoMyx Therapeutics, a privately-held oncolytic immunotherapy company, reported two poster presentations at the upcoming Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)’s (SITC) (Free SITC Whitepaper) 36th Annual Meeting being held November 10-14, 2021, both virtually and in Washington, D.C (Press release, OncoMyx Therapeutics, OCT 20, 2021, View Source [SID1234591590]).

Onsite posters will be presented in the Poster Hall at the Walter E. Washington Convention Center. The posters will be available for onsite viewing November 12-14 from 7am to 5pm EST. Even numbered posters will be presented Saturday, November 13. ePosters will be on display on the SITC (Free SITC Whitepaper) 2021 virtual meeting platform from 7am EST on Friday, November 12 until the virtual meeting platform is closed on January 9, 2022.

Titles of the presentations are as follows:

(742) Multi-armed myxoma virus induces potent anti-tumor responses in vitro and in vivo
(744) Multi-armed myxoma virus has therapeutic potential for treatment of multiple myeloma
Full abstracts will be available on November 9th on the SITC (Free SITC Whitepaper) 2021 Annual Meeting website. Posters for both presentations will be available on OncoMyx’s website on November 12th.

About Oncolytic Immunotherapy and Myxoma Virus

Oncolytic viruses (OV) selectively replicate in and lyse tumor cells and provide stimulation to the immune system, representing a promising therapeutic option in development to treat cancers that do not respond well tOncolytic viruses (OV) selectively replicate in and lyse tumor cells and provide stimulation to the immune system, representing a promising therapeutic option in development to treat cancers that do not respond well to treatment with immune checkpoint inhibitors. Myxoma virus (MYXV) is a member of the Pox family of double stranded DNA viruses. The natural host of MYXV is a subset of rabbits and hares, but MYXV is able to infect cancer cell lines of humans and other species. The genome of MYXV is relatively large and is amenable to engineering for expression of transgenic proteins, making it an excellent oncolytic virus for introduction of immunomodulatory proteins.